POINT Biopharma Global (POINT Biopharma Global) Interest Expense : $0.0 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is POINT Biopharma Global Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. POINT Biopharma Global's interest expense for the three months ended in Sep. 2023 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. POINT Biopharma Global's Operating Income for the three months ended in Sep. 2023 was $ -29.6 Mil. POINT Biopharma Global's Interest Expense for the three months ended in Sep. 2023 was $ 0.0 Mil. GuruFocus does not calculate POINT Biopharma Global's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

POINT Biopharma Global Interest Expense Historical Data

The historical data trend for POINT Biopharma Global's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

POINT Biopharma Global Interest Expense Chart

POINT Biopharma Global Annual Data

Trend

Dec20

Dec21

Dec22

Interest Expense

-0.01

POINT Biopharma Global Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial									-	-	-	-	-

POINT Biopharma Global Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

POINT Biopharma Global (NAS:PNT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

POINT Biopharma Global's Interest Expense for the three months ended in Sep. 2023 was $0.0 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-29.6 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $8.7 Mil.

POINT Biopharma Global's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

GuruFocus does not calculate POINT Biopharma Global's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. POINT Biopharma Global Inc has enough cash to cover all of its debt. Its financial situation is stable.

POINT Biopharma Global (POINT Biopharma Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

4850 West 78th Street, Indianapolis, IN, USA, 46268

Website

https://www.pointbiopharma.com

POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.

Executives

Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bridget A Martell	director	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Joe A. Mccann	director, officer: Chief Executive Officer	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Rajesh Malik	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Gerald L. Hogue	director	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
David Charles Lubner	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472